GE HealthCare Reports First Quarter 2024 Financial Results

Revenues declined 1% year-over-year; Organic revenue growth* was approximately flat

Net income margin was 8.0% versus 7.9% for the prior year; Adjusted Earnings Before Interest and Taxes (EBIT) margin* was 14.7% versus 14.1%

Diluted earnings per share (EPS) were $0.81 versus $0.41 for the prior year; Adjusted EPS* was $0.90 versus $0.85

Cash flow from operating activities was $419 million versus $468 million for the prior year; Free cash flow* was $274 million versus $325 million; repaid $150 million of debt in January 2024

Reaffirming full year 2024 guidance

CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today reported financial results for the first quarter ended March 31, 2024.

GE HealthCare President and CEO Peter Arduini said, “We made good progress against 2024 priorities in the first quarter. We delivered margin expansion, while continuing to invest in innovation to solve the evolving needs of customers and patients. This is reflected in our healthy backlog, orders growth, and positive book-to-bill. We also closed the acquisition of MIM Software earlier this month as we accelerate our precision care strategy. We expect to see business growth weighted toward the second half of 2024 consistent with our previous comments, and we remain on track to deliver our guidance for the year.”

First Quarter 2024 Total Company Financial Performance

Revenues of $4.6 billion declined 1% reported and were approximately flat on an Organic* basis year-over-year, with decreased volume partially offset by positive price.

Total company book-to-bill was solid at 1.03 times, defined as Total orders divided by Total revenues. Total company orders increased 1% organically year-over-year.

Net income attributable to GE HealthCare was $374 million versus $372 million for the prior year, and Adjusted EBIT* was $681 million versus $664 million.

Net income margin was 8.0% versus 7.9% for the prior year, up 10 basis points (bps). Adjusted EBIT margin* was 14.7% versus 14.1%, up 50 bps as both measures saw benefits from productivity and price.

Diluted EPS was $0.81 versus $0.41, up $0.40 from the prior year due to a noncontrolling interest redemption of preferred stock in the prior year. Adjusted EPS* was $0.90 versus $0.85, up $0.05 from the prior year driven by improved margins and lower interest expense.

Cash flow from operating activities was $419 million, down $49 million year-over-year. Free cash flow* was $274 million, down $51 million year-over-year. The Company repaid $150 million of debt in January 2024, as previously disclosed.

First Quarter 2024 Segment Financial Performance (Unaudited)

Segment

($ in millions)

Imaging

Ultrasound

Patient Care

Solutions

Pharmaceutical

Diagnostics

Segment Revenues

$2,466

$824

$747

$599

YoY % change

(1)%

(4)%

(4)%

7%

YoY % Organic* change

~flat

(4)%

(4)%

8%

Segment EBIT

$240

$182

$81

$178

YoY % change

26%

(12)%

(25)%

15%

Segment EBIT Margin

9.7%

22.1%

10.9%

29.7%

YoY change

210 bps

(200) bps

(310) bps

190 bps

YoY refers to year-over-year comparison

Growth and Innovation

Mr. Arduini continued, “In the quarter we made notable progress with our R&D strategy aimed at driving innovation and growth. We received FDA clearances that will allow us to advance our product portfolio, entered strategic research partnerships, and announced long-term collaborations to supply customers with our innovative technology. Our double-digit growth in R&D affirms our commitment to technological advancement, strengthening our new product innovation pipeline, and fueling revenue expansion opportunities.”

Recent Innovation and Commercial Highlights

GE HealthCare Receives FDA Clearance for Portrait VSM, Building on Its Growing Ecosystem of Connected Patient Monitoring Solutions

GE HealthCare’s MIM Software Collaborates with Elekta to Help Enhance Radiation Therapy Treatments and Improve Patient Outcomes

GE HealthCare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

GE HealthCare closes MIM Software Acquisition, Bolstering its Portfolio and Advancing its Precision Care Strategy

GE HealthCare Announces the FDA Clearance of nCommand Lite by IONIC Health

GE HealthCare and Hartford HealthCare Renew and Evolve 7-Year Collaboration to Advance Patient Care and Access in Connecticut

GE HealthCare Announces Publication on Artificial Intelligence Models Leveraging Routinely Collected Clinical Data to Predict Patient Response to Immunotherapy

GE HealthCare Precision Care with Launch of Elevated LOGIQ Ultrasound System Portfolio at European Congress of Radiology 2024

Serving Patients and Communities through Comprehensive Care Solutions: OSF HealthCare, Pointcore, Inc. and GE HealthCare Enter Strategic Care Alliance

2024 Guidance

The Company is reaffirming full year 2024 guidance as follows:

Organic revenue growth* of approximately 4% year-over-year.

Adjusted EBIT margin* in the range of 15.6% to 15.9%, reflecting an expansion of 50 to 80 basis points versus 2023 Adjusted EBIT margin* of 15.1%.

Adjusted effective tax rate (ETR)* in the range of 23% to 25%.

Adjusted EPS* in the range of $4.20 to $4.35, representing 7% to 11% growth versus Adjusted EPS* of $3.93 for 2023.

Free cash flow* of approximately $1.8 billion.

The Company provides its outlook on a non-GAAP basis. Refer to the Non-GAAP Financial Measures in Outlook section below for more details.

Financial Rounding

Certain columns and rows in this document may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.

Condensed Consolidated Statements of Income (Unaudited)

 

For the three months ended March 31

(In millions, except per share amounts)

2024

2023

Sales of products

$

3,045

 

$

3,131

 

Sales of services

 

1,605

 

 

1,576

 

Total revenues

 

4,650

 

 

4,707

 

Cost of products

 

1,967

 

 

2,037

 

Cost of services

 

782

 

 

779

 

Gross profit

 

1,902

 

 

1,891

 

Selling, general, and administrative

 

1,038

 

 

1,062

 

Research and development

 

324

 

 

270

 

Total operating expenses

 

1,362

 

 

1,332

 

Operating income

 

540

 

 

559

 

Interest and other financial charges – net

 

122

 

 

136

 

Non-operating benefit (income) costs

 

(102

)

 

(115

)

Other (income) expense – net

 

8

 

 

(8

)

Income before income taxes

 

512

 

 

546

 

Benefit (provision) for income taxes

 

(124

)

 

(163

)

Net income

 

388

 

 

383

 

Net (income) loss attributable to noncontrolling interests

 

(14

)

 

(11

)

Net income attributable to GE HealthCare

 

374

 

 

372

 

Deemed preferred stock dividend of redeemable noncontrolling interest

 

 

 

(183

)

Net income attributable to GE HealthCare common stockholders

$

374

 

$

189

 

 

 

 

Earnings per share attributable to GE HealthCare common stockholders:

 

 

Basic

$

0.82

 

$

0.42

 

Diluted

$

0.81

 

$

0.41

 

Weighted-average number of shares outstanding:

 

 

Basic

 

456

 

 

454

 

Diluted

 

459

 

 

457

 

Condensed Consolidated Statements of Financial Position (Unaudited)

 

As of

(In millions, except share and per share amounts)

March 31, 2024

December 31, 2023

Cash, cash equivalents, and restricted cash

$

2,563

 

$

2,504

 

Receivables – net of allowances of $102 and $98

 

3,324

 

 

3,525

 

Due from related parties

 

20

 

 

32

 

Inventories

 

1,989

 

 

1,960

 

Contract and other deferred assets

 

961

 

 

1,000

 

All other current assets

 

517

 

 

389

 

Current assets

 

9,373

 

 

9,410

 

Property, plant, and equipment – net

 

2,445

 

 

2,500

 

Goodwill

 

12,927

 

 

12,936

 

Other intangible assets – net

 

1,174

 

 

1,253

 

Deferred income taxes

 

4,413

 

 

4,474

 

All other non-current assets

 

1,878

 

 

1,881

 

Total assets

$

32,208

 

$

32,454

 

Short-term borrowings

$

1,008

 

$

1,006

 

Accounts payable

 

2,931

 

 

2,947

 

Due to related parties

 

48

 

 

99

 

Contract liabilities

 

1,879

 

 

1,918

 

All other current liabilities

 

2,993

 

 

3,011

 

Current liabilities

 

8,859

 

 

8,981

 

Long-term borrowings

 

8,247

 

 

8,436

 

Compensation and benefits

 

5,625

 

 

5,782

 

Deferred income taxes

 

68

 

 

68

 

All other non-current liabilities

 

1,811

 

 

1,877

 

Total liabilities

 

24,609

 

 

25,144

 

Commitments and contingencies

 

 

Redeemable noncontrolling interests

 

177

 

 

165

 

Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 456,328,270 shares issued and outstanding as of March 31, 2024; 455,342,290 shares issued and outstanding as of December 31, 2023

 

5

 

 

5

 

Additional paid-in capital

 

6,504

 

 

6,493

 

Retained earnings

 

1,687

 

 

1,326

 

Accumulated other comprehensive income (loss) – net

 

(787

)

 

(691

)

Total equity attributable to GE HealthCare

 

7,408

 

 

7,133

 

Noncontrolling interests

 

14

 

 

12

 

Total equity

 

7,423

 

 

7,145

 

Total liabilities, redeemable noncontrolling interests, and equity

$

32,208

 

$

32,454

 

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

For the three months ended March 31

(In millions)

2024

2023

Net income

$

388

 

$

383

 

Adjustments to reconcile Net income to Cash from (used for) operating activities

 

 

Depreciation of property, plant, and equipment

 

68

 

 

61

 

Amortization of intangible assets

 

80

 

 

96

 

Gain on fair value remeasurement of contingent consideration

 

(1

)

 

 

Net periodic postretirement benefit plan (income) expense

 

(90

)

 

(101

)

Postretirement plan contributions

 

(87

)

 

(91

)

Share-based compensation

 

34

 

 

24

 

Provision for income taxes

 

124

 

 

163

 

Cash paid during the year for income taxes

 

(86

)

 

(102

)

Changes in operating assets and liabilities, excluding the effects of acquisitions:

 

 

Receivables

 

155

 

 

(22

)

Due from related parties

 

13

 

 

5

 

Inventories

 

(59

)

 

(122

)

Contract and other deferred assets

 

32

 

 

12

 

Accounts payable

 

81

 

 

87

 

Due to related parties

 

(50

)

 

6

 

Contract liabilities

 

(18

)

 

119

 

All other operating activities

 

(165

)

 

(50

)

Cash from (used for) operating activities

 

419

 

 

468

 

Cash flows – investing activities

 

 

Additions to property, plant and equipment and internal-use software

 

(145

)

 

(143

)

Purchases of businesses, net of cash acquired

 

 

 

(127

)

All other investing activities

 

(42

)

 

4

 

Cash from (used for) investing activities

 

(188

)

 

(266

)

Cash flows – financing activities

 

 

Net increase (decrease) in borrowings (maturities of 90 days or less)

 

1

 

 

(9

)

Newly issued debt, net of debt issuance costs (maturities longer than 90 days)

 

1

 

 

2,000

 

Repayments and other reductions (maturities longer than 90 days)

 

(153

)

 

(6

)

Dividends paid to stockholders

 

(14

)

 

 

Net transfers (to) from GE

 

 

 

(1,317

)

All other financing activities

 

12

 

 

5

 

Cash from (used for) financing activities

 

(153

)

 

673

 

Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash

 

(19

)

 

8

 

Increase (decrease) in cash, cash equivalents, and restricted cash

 

59

 

 

883

 

Cash, cash equivalents, and restricted cash at beginning of year

 

2,506

 

 

1,451

 

Cash, cash equivalents, and restricted cash as of March 31

$

2,565

 

$

2,334

 

 

 

 

Supplemental disclosure of cash flows information

 

 

Cash paid during the year for interest

$

(55

)

$

(42

)

Non-cash investing activities

 

 

Acquired but unpaid property, plant, and equipment

$

53

 

$

64

 

Non-GAAP Financial Measures

The non-GAAP financial measures presented in this press release are supplemental measures of GE HealthCare’s performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results and assess its future prospects. The Company believes that presenting these non-GAAP financial measures, in addition to the corresponding U.S. GAAP financial measures, are important supplemental measures that exclude non-cash or other items that may not be indicative of or related to its core operating results and the overall health of the Company. The Company believes these non-GAAP financial measures provide investors greater transparency to the information used by management for its operational decision-making and allow investors to see results “through the eyes of management.” The Company further believes that providing this information assists investors in understanding its operating performance and the methodology used by management to evaluate and measure such performance. When read in conjunction with the Company’s U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in the Company’s underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Finally, these measures are often used by analysts and other interested parties to evaluate companies in the Company’s industry.

Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes, thereby affecting their comparability from company to company. In order to compensate for these and the other limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. Readers should review the reconciliations and should not rely on any single financial measure to evaluate the Company’s business.

The Company defines these non-GAAP financial measures as:

Organic revenue: Total revenues excluding the effects of: (1) net sales from recent acquisitions and dispositions with less than a full year of comparable net sales; and (2) foreign currency exchange rate fluctuations in order to present revenue on a constant currency basis.

Organic revenue growth rate: Rate of change when comparing Organic revenue, period over period.

EBIT: Net income attributable to GE HealthCare excluding the effects of: (1) Interest and other financial charges – net; (2) Non-operating benefit (income) costs; (3) Provision (benefit) for income taxes; (4) Income (loss) from discontinued operations, net of taxes; (5) Net (income) loss attributable to noncontrolling interests.

Adjusted EBIT: Net income attributable to GE HealthCare excluding the effects of: (1) Interest and other financial charges – net; (2) Non-operating benefit (income) costs; (3) Provision (benefit) for income taxes; (4) Income (loss) from discontinued operations, net of taxes; (5) Net (income) loss attributable to noncontrolling interests; (6) restructuring costs; (7) acquisition and disposition-related charges (benefits); (8) Spin-Off and separation costs; (9) (gain) loss on business and asset dispositions; (10) amortization of acquisition-related intangible assets; and (11) investment revaluation (gain) loss. In addition, the Company may from time to time consider excluding other nonrecurring items to enhance comparability between periods.

Adjusted EBIT margin: Adjusted EBIT divided by Total revenues for the same period.

The Company believes that Organic revenue and Organic revenue growth rate, by excluding the effect of acquisitions, dispositions, and foreign currency rate fluctuations, provide management and investors with additional understanding of the Company’s core, top-line operating results and greater visibility into underlying revenue trends of its established, ongoing operations. Organic revenue and Organic revenue growth rate also provide greater insight regarding the overall demand for its products and services.

The Company believes EBIT, Adjusted EBIT, and Adjusted EBIT margin provide management and investors with additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors. These metrics exclude interest expense, interest income, non-operating benefit (income) costs, and tax expense, as well as non-recurring and/or non-cash items, which may have a material impact on the Company’s results. The Company believes this provides additional insight into how its businesses are performing, on a normalized basis. However, these non-GAAP financial measures should not be construed as inferring that the Company’s future results will be unaffected by the items for which the measure adjusts.​

Adjusted net income: Net income attributable to GE HealthCare excluding (1) Non-operating benefit (income) costs; (2) restructuring costs; (3) acquisition and disposition-related charges (benefits); (4) Spin-Off and separation costs; (5) (gain) loss on business and asset dispositions; (6) amortization of acquisition-related intangible assets; (7) investment revaluation (gain) loss; (8) tax effect of reconciling items (items 1-7); (9) certain tax adjustments as described in Adjusted tax expense definition below and (10) Income (loss) from discontinued operations, net of taxes. In addition, the Company may from time to time consider excluding other nonrecurring items to enhance comparability between periods.

Adjusted EPS: Diluted earnings per share excluding the per share impact of: (1) deemed preferred stock dividend of redeemable noncontrolling interest, (2) Non-operating benefit (income) costs; (3) restructuring costs; (4) acquisition and disposition-related charges (benefits); (5) Spin-Off and separation costs; (6) (gain) loss on business and asset dispositions; (7) amortization of acquisition-related intangible assets; (8) investment revaluation (gain) loss; (9) tax effect of reconciling items (items 1-8); and (10) certain tax adjustments as described in Adjusted tax expense definition below. In addition, the Company may from time to time consider excluding other nonrecurring items to enhance comparability between periods.

The Company believes Adjusted net income and Adjusted EPS provide investors with improved comparability of underlying operating results and a further understanding and additional transparency regarding how it evaluates the business. These non-GAAP financial measures also provide management and investors with additional perspective regarding the impact of certain significant items on the Company’s earnings. However, they should not be construed as inferring that the Company’s future results will be unaffected by the items for which the measure adjusts.​

Adjusted tax expense and Adjusted ETR: Adjusted tax expense is Income tax expense less the income tax related to pre-tax income adjustments above and certain income tax adjustments. Examples of certain income tax adjustments include the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested. Adjusted ETR is Adjusted tax expense divided by Income before income taxes less pre-tax income adjustments above.

The Company believes that Adjusted tax expense and Adjusted ETR provide investors with a better understanding of the normalized tax rate applicable to the Company’s business and provide more consistent comparability across periods.

Free cash flow: Cash from (used for) operating activities adjusting for the effects of (1) additions to property, plant and equipment (PP&E) and internal-use software; and (2) dispositions of PP&E.

Free cash flow conversion: Free cash flow divided by Adjusted net income.

The Company believes that Free cash flow and Free cash flow conversion provide management and investors with important measures of the Company’s ability to generate cash on a normalized basis. These metrics also provide insight into the Company’s flexibility to allocate capital, including reinvesting in the Company for future growth, paying down debt, paying dividends, and pursuing other opportunities that may enhance stockholder value. However, they should not be construed as inferring that the Company’s future results will be unaffected by the items for which the measure adjusts.

Non-GAAP Financial Reconciliations

 

Organic Revenue*

 

 

 

Unaudited

For the three months ended March 31

($ In millions)

2024

2023

% change

Imaging revenues

$

2,466

 

$

2,496

(1

)%

Less: Acquisitions(1)

 

 

 

 

Less: Dispositions(2)

 

 

 

 

Less: Foreign currency exchange

 

(27

)

 

 

Imaging Organic revenue*

$

2,493

 

$

2,496

%

Ultrasound revenues

$

824

 

$

859

(4

)%

Less: Acquisitions(1)

 

 

 

 

Less: Dispositions(2)

 

 

 

 

Less: Foreign currency exchange

 

(5

)

 

 

Ultrasound Organic revenue*

$

829

 

$

859

(4

)%

PCS revenues

$

747

 

$

781

(4

)%

Less: Acquisitions(1)

 

 

 

 

Less: Dispositions(2)

 

 

 

 

Less: Foreign currency exchange

 

(1

)

 

 

PCS Organic revenue*

$

748

 

$

781

(4

)%

PDx revenues

$

599

 

$

558

7

%

Less: Acquisitions(1)

 

 

 

 

Less: Dispositions(2)

 

 

 

 

Less: Foreign currency exchange

 

(1

)

 

 

PDx Organic revenue*

$

600

 

$

558

8

%

Other revenues

$

15

 

$

13

12

%

Less: Acquisitions(1)

 

 

 

 

Less: Dispositions(2)

 

 

 

 

Less: Foreign currency exchange

 

 

 

 

Other Organic revenue*

$

14

 

$

13

11

%

Total revenues

$

4,650

 

$

4,707

(1

)%

Less: Acquisitions(1)

 

 

 

 

Less: Dispositions(2)

 

 

 

 

Less: Foreign currency exchange

 

(34

)

 

 

Organic revenue*

$

4,684

 

$

4,707

%

(1)

Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.

(2)

Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

Adjusted EBIT*

Unaudited

For the three months ended March 31

($ In millions)

2024

2023

% change

Net income attributable to GE HealthCare

$

374

 

$

372

 

%

Add: Interest and other financial charges – net

 

122

 

 

136

 

 

Add: Non-operating benefit (income) costs

 

(102

)

 

(115

)

 

Less: Benefit (provision) for income taxes

 

(124

)

 

(163

)

 

Less: Net (income) loss attributable to noncontrolling interests

 

(14

)

 

(11

)

 

EBIT*

$

531

 

$

567

 

(6

)%

Add: Restructuring costs(1)

 

40

 

 

12

 

 

Add: Acquisition and disposition-related charges (benefits)(2)

 

 

 

1

 

 

Add: Spin-Off and separation costs(3)

 

60

 

 

58

 

 

Add: (Gain) loss on business and asset dispositions(4)

 

 

 

 

 

Add: Amortization of acquisition-related intangible assets

 

31

 

 

31

 

 

Add: Investment revaluation (gain) loss(5)

 

20

 

 

(5

)

 

Adjusted EBIT*

$

681

 

$

664

 

3

%

Net income margin

 

8.0

%

 

7.9

%

10 bps

Adjusted EBIT margin*

 

14.7

%

 

14.1

%

50 bps

(1)

Consists of severance, facility closures, and other charges associated with restructuring programs.

(2)

Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3)

Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.

(4)

Consists of gains and losses resulting from the sale of assets and investments.

(5)

Primarily relates to valuation adjustments for equity investments.

Adjusted Net Income*

Unaudited

For the three months ended March 31

($ In millions)

2024

2023

% change

Net income attributable to GE HealthCare

$

374

 

$

372

 

%

Add: Non-operating benefit (income) costs

 

(102

)

 

(115

)

 

Add: Restructuring costs(1)

 

40

 

 

12

 

 

Add: Acquisition and disposition-related charges (benefits)(2)

 

 

 

1

 

 

Add: Spin-Off and separation costs(3)

 

60

 

 

58

 

 

Add: (Gain) loss on business and asset dispositions(4)

 

 

 

 

 

Add: Amortization of acquisition-related intangible assets

 

31

 

 

31

 

 

Add: Investment revaluation (gain) loss(5)

 

20

 

 

(5

)

 

Add: Tax effect of reconciling items

 

(9

)

 

4

 

 

Add: Certain tax adjustments(6)

 

 

 

30

 

 

Adjusted net income*

$

413

 

$

388

 

6

%

Adjusted net income margin*

 

8.9

%

 

8.2

%

60 bps

(1)

Consists of severance, facility closures, and other charges associated with restructuring programs.

(2)

Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3)

Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.

(4)

Consists of gains and losses resulting from the sale of assets and investments.

(5)

Primarily relates to valuation adjustments for equity investments.

(6)

Consists of certain income tax adjustments, including the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested and the impact of adjusting deferred tax assets and liabilities to stand-alone GE HealthCare tax rates.

Contacts

Investor Relations Contact:
Carolynne Borders

+1-631-662-4317

[email protected]

Media Contact:
Tor Constantino

+1-585-441-1658

[email protected]

Read full story here

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.